ALRN - エイルロン・セラピュ―ティクス (Aileron Therapeutics Inc.) エイルロン・セラピュ―ティクス

 ALRNのチャート


 ALRNの企業情報

symbol ALRN
会社名 Aileron Therapeutics Inc (エイルロン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エルロン・セラピューティクス(Aileron Therapeutics Inc.)は米国を拠点とする臨床段階のバイオ医薬品会社である。同社はステープルペプチドと呼ばれる治療薬を開発し、商品化する。同社はまた、癌、内分泌および代謝性疾患および炎症を含む治療領域にわたってステープルペプチド薬物パイプラインを開発する。同社は固型と血液悪性腫瘍のスペクトルにおいて有効性・安全性を提供するリード・オンコロジー・プログラムを提供する。同社のリード製品候補ALRN-6924は癌の治療用腫瘍抑制タンパク質p53を標的とする。同社は標準的療法に非突然変異型・野生型p53を発現する固形腫瘍・リンパ腫を有する成人患者において、ALRN-6924の第I相臨床試験を実施する。ALRN-6924は天然p53サプレッサータンパク質のマウス(MDM2)およびMDMXを標的とすることによって、p53媒介細胞死を再活性化できる。   エイルロン・セラピュ―ティクスはアメリカのバイオ医薬品企業。臨床段階で、治療用ペプチド薬品の開発・商品化に従事する。がん、内分泌および代謝性疾患、炎症などの治療用ペプチドを開発し、同社パイプライン「ALRN-6924」は多種多様ながんの治療向けに腫瘍抑制因子p53をタ―ゲットとする。本社はマサチュ―セッツ州ケンブリッジ。   
本社所在地 281 Albany Street Cambridge MA 02139 USA
代表者氏名 Jeffrey A. Bailey ジェフリー・A・ベイリー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-995-0900
設立年月日 37104
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.aileronrx.com
nasdaq_url https://www.nasdaq.com/symbol/alrn
adr_tso
EBITDA EBITDA(百万ドル) -30.72300
終値(lastsale) 2.68
時価総額(marketcap) 39496237.36
時価総額 時価総額(百万ドル) 38.31725
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 5.87125
当期純利益 当期純利益(百万ドル) -30.20300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aileron Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 79% to $17.1M. Higher net loss reflects Research and development increase of 64% to $9.7M (expense) General and administrative increase of 79% to $5.7M (expense) Stock-based Compensation in SGA increase from $264K to $1.6M (expense).

 ALRNのテクニカル分析


 ALRNのニュース

   Thinking about buying stock in Pfizer, Senseonics Holdings, AIM ImmunoTech, Aileron Therapeutics, or Microvision?  2020/12/24 13:31:00 PR Newswire
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, SENS, AIM, ALRN, and MVIS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Aileron Therapeutics EPS in-line (NASDAQ:ALRN)  2020/11/13 03:28:01 Seeking Alpha
Aileron Therapeutics (NASDAQ:ALRN): Q3 GAAP EPS of -$0.13 in-line. Cash, cash equivalents and investments of $14.1M. Press Release
   Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights - Stocks News Feed  2020/11/13 00:03:00 Stocks News Feed
Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation at 2020 EORTC-NCI-AACR Annual Symposium Phase 1b randomized, controlled trial in patients with p53-mutated advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy projected to start in the second… Read More »Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout  2020/10/15 12:03:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.
   Thinking about buying stock in Pfizer, Senseonics Holdings, AIM ImmunoTech, Aileron Therapeutics, or Microvision?  2020/12/24 13:31:00 PR Newswire
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, SENS, AIM, ALRN, and MVIS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Aileron Therapeutics EPS in-line (NASDAQ:ALRN)  2020/11/13 03:28:01 Seeking Alpha
Aileron Therapeutics (NASDAQ:ALRN): Q3 GAAP EPS of -$0.13 in-line. Cash, cash equivalents and investments of $14.1M. Press Release
   Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights - Stocks News Feed  2020/11/13 00:03:00 Stocks News Feed
Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation at 2020 EORTC-NCI-AACR Annual Symposium Phase 1b randomized, controlled trial in patients with p53-mutated advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy projected to start in the second… Read More »Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout  2020/10/15 12:03:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.
   Aileron Therapeutics inks $15M stock purchase deal with Lincoln Park Capital (NASDAQ:ALRN)  2020/09/22 04:23:43 Seeking Alpha
Aileron Therapeutics (NASDAQ:ALRN) inks an agreement with Lincoln Park Capital Fund, under which latter will purchase up to $15M of its common stock over a
   Aileron Prices Dip on Common Stock Offering  2020/06/04 13:42:52 Baystreet Canada
Aileron Therapeutics Inc (NASDAQ:ALRN) reported a proposed public offering of common stock. The Watertown, Mass.-based company said the offering, announced at the close of business Wednesday, provides for a 30-day option to purchase up to an additional …
   The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics  2020/06/02 14:22:00 Zacks Investment Research
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant  2020/05/29 11:22:24 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI ) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エイルロン・セラピュ―ティクス ALRN Aileron Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)